FDA Approves Tecentriq for Colon Cancer, Expanding Roche's Oncology Reach
RHHBY sits 33% above its 52-week low of $40.07.
Summary
Genentech's Tecentriq received FDA approval for a new colon cancer indication, broadening the drug's label and opening a significant patient population. This is the first report of this specific approval; the timeline shows recent positive regulatory momentum for Roche, including European approval of Susvimo and FDA priority review for fenebrutinib. The new indication adds a meaningful revenue stream for Tecentriq, which is already a key oncology franchise. No specific upcoming event is named in the source.
At the time of this announcement, RHHBY was trading at $53.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $344.7B. The 52-week trading range was $40.07 to $60.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.